アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
Synthetic peptide conjugated to KLH derived from within residues 200 - 300 of Human Runx1/AML1.
(Peptide available as ab24287.)
Our Abpromise guarantee covers the use of ab23980 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ChIP||Use at an assay dependent concentration.|
|EMSA||Use at an assay dependent concentration. PubMed: 22253448|
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 52 kDa (predicted molecular weight: 48 kDa).|
|CHIPseq||Use at an assay dependent concentration. PubMed: 24760698|
|ICC/IF||Use at an assay dependent concentration.|
|IP||Use at an assay dependent concentration. PubMed: 21151104|
ChIP analysis using unpurified ab23980 binding RUNX1 / AML1 in the nuclear lysate of mouse haematopoietic progenitor cell line HPC-7. Cells were cross-linked for 10 minutes with 1% formaldehyde. Samples were incubated with undiluted primary antibody for 16 hours at 4°C. Protein binding was detected using real-time PCR.
Positive control: a competitor antibody to a postive region known to bind this transcription factor.
Negative Control: a regulatory region known to be devoid of this transcription factor.
Note - 14ug of antibody per 20,000,000 million cells was used in this test. However, this experiment was then tested with 5-7ug of antibody and the same result was obtained.
ab23980 staining RUNX1 / AML1 in human glioblastoma cells by Immunocytochemistry/ Immunofluorescence. The cells were fixed in paraformaldehyde, permeabilised in 0.1% Triton X-100 and then blocked using 0.5% BSA for 20 minutes. Samples were then incubated with primary antibody at 1/50 for 16 hours at 4°C. The secondary antibody used was a goat anti-rabbit IgG conjugated to FITC used at a 1/400 dilution. Nuclei are counterstained with DAPI